【摘要】：目的：觀察Ⅰ類組蛋白脫乙�；�(HDAC)抑制劑4SC-202體內(nèi)外抗結(jié)腸癌細(xì)胞的作用,旨在為結(jié)腸癌的分子靶向治療進(jìn)行新的探索。方法：1)MTT法、臺(tái)盼藍(lán)染色法、細(xì)胞集落試驗(yàn)檢測(cè)不同濃度的4SC-202處理不同作用時(shí)間后對(duì)結(jié)腸癌細(xì)胞存活、細(xì)胞死亡及細(xì)胞增殖的影響；2) Histone DNA ELISA法、Caspase-3/-9試劑盒方法、Annexin V-PI流式細(xì)胞儀法檢測(cè)4SC-202對(duì)結(jié)腸癌細(xì)胞凋亡的作用；4SC-202處理后對(duì)其抗凋亡蛋白Bcl-2的表達(dá)進(jìn)行檢測(cè),運(yùn)用的方法為Western Blotting;3) PI流式細(xì)胞儀法觀察4SC-202處理結(jié)腸癌細(xì)胞后,細(xì)胞周期的變化。4)用藥理學(xué)和shRNA等手段抑制結(jié)腸癌細(xì)胞內(nèi)AKT的活性,觀察抑制后4SC-202體外抗結(jié)腸癌細(xì)胞活性的變化。5)MTT法、Histone DNA ELISA法等方法檢測(cè)比較奧沙利鉑組、4SC-202組以及奧沙利鉑聯(lián)合4SC-202組對(duì)結(jié)腸癌細(xì)胞的存活和凋亡的影響。6)建立裸鼠荷瘤模型,觀察奧沙利鉑和/或4SC-202在體內(nèi)抗結(jié)腸癌細(xì)胞活性。結(jié)果：1)4SC-202顯著抑制結(jié)腸癌細(xì)胞(原代人結(jié)腸癌細(xì)胞和HT-29,HCT-116,HT-15,DLD-1細(xì)胞株)的存活和增殖,其抑制作用呈時(shí)間和濃度依賴性。2)4SC-202誘導(dǎo)結(jié)腸癌細(xì)胞凋亡。4SC-202可以抑制抗凋亡蛋白Bcl-2的表達(dá)。3)當(dāng)4SC-202濃度不斷的增大時(shí),結(jié)腸癌細(xì)胞的G1和S期所占比例逐漸減少,G2-M期比例增加。4)添加AKT選擇性抑制劑perifosine、MK-2206或shRNA敲減AKT1/2顯著增加4SC-202誘導(dǎo)的體外抗結(jié)腸癌細(xì)胞的活性。而導(dǎo)入持續(xù)活化的AKT1(CA-AKT1)則抑制4SC-202抗結(jié)腸癌細(xì)胞的作用。5)奧沙利鉑誘導(dǎo)的體外抗結(jié)腸癌細(xì)胞的活性在有低濃度4SC-202存在時(shí)明顯增強(qiáng)。兩者協(xié)同給藥誘導(dǎo)的抗結(jié)腸癌細(xì)胞的活性要顯著強(qiáng)于單獨(dú)給藥。6)在裸鼠荷瘤模型中,4SC-202 (100mg/kg, Q2D)口服給藥顯著抑制HT-29移植瘤的在體生長(zhǎng)。而同時(shí)腹腔注射奧沙利鉑(5.0mg/kg, Q3D)則進(jìn)一步增強(qiáng)4SC-202在體抗癌活性。結(jié)論：1)4SC-202濃度及時(shí)間依賴性的抑制人結(jié)腸癌細(xì)胞存活、增殖,并誘導(dǎo)癌細(xì)胞凋亡；2)4SC-202誘導(dǎo)結(jié)腸癌細(xì)胞G2-M周期停滯；3)抑制AKT能增強(qiáng)結(jié)腸癌細(xì)胞對(duì)4SC-202的敏感性；4)4SC-202增強(qiáng)奧沙利鉑體外抗結(jié)腸癌細(xì)胞的作用；5)4SC-202和奧沙利鉑協(xié)同抑制HT-29移植瘤的在體生長(zhǎng)。
[Abstract]:Aim: to observe the effect of class I histone deacetylase (HDAC) inhibitor 4SC-202 on colon cancer cells in vitro and in vivo in order to explore the molecular targeting therapy of colon cancer. Methods: 1) MTT assay, trypan blue staining and cell colony test were used to detect the effects of different concentrations of 4SC-202 on the survival, cell death and cell proliferation of colon cancer cells. 2) Histone DNA ELISA assay, Caspase-3/-9 kit method and Annexin V-PI flow cytometry were used to detect the effect of 4SC-202 on apoptosis of colon cancer cells. After 4SC-202 treatment, the expression of anti-apoptosis protein Bcl-2 was detected by Western Blotting;. 3) PI flow cytometry was used to observe the changes of cell cycle in colon cancer cells treated with 4SC-202. 4) Pharmacology and shRNA were used to inhibit the activity of AKT in colon cancer cells. To observe the changes of anti-colon cancer cell activity of 4SC-202 in vitro after inhibition. 5) MTT, Histone DNA ELISA assay was used to detect and compare the activity of oxaliplatinum group. The effects of 4SC-202 group and oxaliplatin combined with 4SC-202 group on the survival and apoptosis of colon cancer cells. 6) the tumor-bearing model of nude mice was established to observe the anti-colon cancer cell activity of oxaliplatin and / or 4SC-202 in vivo. Results: 1) 4SC-202 significantly inhibited the survival and proliferation of colon cancer cells (primary human colon cancer cells and HT-29,HCT-116,HT-15,DLD-1 cell lines). The inhibitory effect was time-and concentration-dependent. 2) 4SC-202 induced apoptosis in colon cancer cells. 4SC-202 could inhibit the expression of anti-apoptosis protein Bcl-2. 3) when the concentration of 4SC-202 increased, The proportion of G _ 1 and S phase of colon cancer cells decreased gradually, while the proportion of G _ 2-M phase increased. 4) the addition of AKT selective inhibitor perifosine,MK-2206 or shRNA knockdown AKT1/2 significantly increased the activity of 4SC-202-induced anti-colon cancer cells in vitro. However, the introduction of continuously activated AKT1 (CA-AKT1) inhibited the anti-colon cancer cell effect of 4SC-202. 5) the activity of oxaliplatin induced anti-colon cancer cells in vitro was significantly enhanced in the presence of low concentration of 4SC-202. The activity of anti-colon cancer cells induced by co-administration was significantly stronger than that induced by single administration. 6) in nude mice tumor-bearing model, oral administration of 4SC-202 (100mg / kg, Q2D) significantly inhibited the growth of HT-29 transplantable tumor in vivo. At the same time, intraperitoneal injection of oxaliplatin (5.0 mg 路kg / kg, Q3D) further enhanced the anticancer activity of 4SC-202 in vivo. Conclusion: 1) 4SC-202 can inhibit the survival, proliferation and apoptosis of human colon cancer cells in a concentration-and time-dependent manner, 2) 4SC-202 can induce the arrest of G2 / M cycle of colon cancer cells. 3) inhibition of AKT could enhance the sensitivity of colon cancer cells to 4SC-202, 4) 4SC-202 enhanced the anti-colon cancer cell effect of oxaliplatin in vitro, and 5) 4SC-202 and oxaliplatin combined with oxaliplatin could inhibit the growth of HT-29 transplantation tumor in vivo.
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R96

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 胡平,琚立華,徐元鼎;結(jié)腸癌細(xì)胞核DNA含量測(cè)量及形態(tài)分析[J];復(fù)旦學(xué)報(bào)(醫(yī)學(xué)版);2003年05期

2 王春暉;歐陽(yáng)欽;唐承薇;黃明慧;李獻(xiàn);;選擇性及非選擇性COX-2抑制劑對(duì)結(jié)腸癌細(xì)胞生長(zhǎng)的影響[J];四川大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2006年04期

3 韓忠寶;李洪祥;楊翊研;;生長(zhǎng)抑素聯(lián)合阿霉素體外抑制結(jié)腸癌細(xì)胞的實(shí)驗(yàn)研究[J];吉林醫(yī)學(xué);2006年09期

4 張朝陽(yáng);徐克森;楊廣運(yùn);王金申;高穎;劉炎峰;帥晶;王家勇;李少燕;壽楠海;牛軍;;反義整合素β6基因?qū)Y(jié)腸癌細(xì)胞作用的研究[J];中華醫(yī)學(xué)雜志;2007年37期

5 沈丹;鄧長(zhǎng)生;;過氧化物酶體增殖物激活受體γ在結(jié)腸癌中的表達(dá)及其激動(dòng)劑對(duì)結(jié)腸癌細(xì)胞的生長(zhǎng)抑制作用[J];臨床內(nèi)科雜志;2008年01期

6 田永剛;許軍;劉昶;;人工氣腹對(duì)結(jié)腸癌細(xì)胞生物學(xué)行為的影響[J];腹腔鏡外科雜志;2009年10期

7 高喜廉，傅志民，，姜宗源;結(jié)腸癌細(xì)胞腸壁縱向浸潤(rùn)與臨床意義[J];中國(guó)醫(yī)科大學(xué)學(xué)報(bào);1994年03期

8 鄭平菊,黃威權(quán),王瑞安,孫嵐,高平;5-羥色胺及其受體在結(jié)腸癌細(xì)胞的免疫組織化學(xué)定位[J];科學(xué)通報(bào);1995年21期

9 林潔;黃瓊;來(lái)茂德;;5-氮-2′-脫氧胞苷對(duì)結(jié)腸癌細(xì)胞生物學(xué)行為的影響[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2008年04期

10 王德力;齊東麗;;光鑷?yán)庾V技術(shù)檢測(cè)結(jié)腸癌細(xì)胞的研究[J];長(zhǎng)春大學(xué)學(xué)報(bào);2009年04期

相關(guān)會(huì)議論文 前10條

1 許峰;王杉;葉穎江;崔志榮;;腫瘤浸潤(rùn)淋巴細(xì)胞在結(jié)腸癌細(xì)胞殺傷中的作用及機(jī)制[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)消化病學(xué)術(shù)會(huì)議論文匯編（下冊(cè)）[C];2007年

2 王貴玉;王錫山;;激光捕獲微切割技術(shù)分離結(jié)腸癌細(xì)胞用于蛋白組學(xué)研究[A];中國(guó)蛋白質(zhì)組學(xué)第三屆學(xué)術(shù)大會(huì)論文摘要[C];2005年

3 沈丹;鄧長(zhǎng)生;;過氧化物酶體增殖物激活受體γ在結(jié)腸癌中的表達(dá)及其激動(dòng)劑對(duì)結(jié)腸癌細(xì)胞的生長(zhǎng)抑制作用[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)消化病學(xué)術(shù)會(huì)議論文匯編（下冊(cè)）[C];2007年

4 郭俊明;賴依峰;肖丙秀;劉瓊;;大豆異黃酮對(duì)體外培養(yǎng)的結(jié)腸癌細(xì)胞生長(zhǎng)和細(xì)胞周期的影響[A];華東六省一市生物化學(xué)與分子生物學(xué)會(huì)2003年學(xué)術(shù)交流會(huì)論文摘要集[C];2003年

5 李本輝;楊賢子;張文杰;;人類結(jié)腸癌細(xì)胞缺陷型Stat6~(null)活化表型與癌細(xì)胞高凋亡率及低侵襲轉(zhuǎn)移力相關(guān)[A];湖北省抗癌協(xié)會(huì)青年委員會(huì)成立大會(huì)暨第一屆青年學(xué)術(shù)論壇資料匯編[C];2009年

6 王國(guó)強(qiáng);方m錁

本文編號(hào)：2488502